Millennium Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Millennium Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-108,600	Closed	-$2.43M	–	4302
2018 Q1	$2.43M	Buy	+108,600	New	+$2.41M	﹤0.01%	2198

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Millennium Management's JNCE Position: Q2 2023 in Review

Millennium Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 500,000 shares — an estimated $925K sold.

Millennium Management first reported a position in JNCE in Q1 2017 and held it in 21 quarters. The position peaked at $6.46M in Q1 2017. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Millennium Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Millennium Management sold 500,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $925K.
Millennium Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 21 quarters.
Millennium Management's Jounce Therapeutics, Inc. Common Stock position peaked at $6.46M in Q1 2017.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.